Study guide

10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV

WHNP-BC Women's Health Nurse Practitioner Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction: About the WHNP-BC Exam

WHNP-BC Exam Facts, Blueprint & Study Plan

2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening

1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening

3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention

2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites

4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers

3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers

5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility

4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies

6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy

5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion

7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health

6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis

8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care

7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction

9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care

8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy

10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth

9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency

11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions

10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn

12 Chapter 11: Intrapartum Principles & Fetal Surveillance

11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies

13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications

12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs

14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions

13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold

15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders

14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders

16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health

15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis

17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care

16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care

18 Chapter 17: Assessment, Diagnostic Testing & Interpretation

17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities

19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing

18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation

20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities

19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care

10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV

Key Takeaways Explain This Topic AI

Cytomegalovirus is the most common congenital infection and the leading non-genetic cause of sensorineural hearing loss; prevention relies on hygiene around young children's saliva and urine.

Parvovirus B19 can cause fetal anemia and hydrops, most often when infection occurs before 20 weeks, so an infected pregnant patient needs serial middle cerebral artery Doppler studies for 8–12 weeks.

A varicella-susceptible pregnant patient exposed to chickenpox should receive varicella-zoster immune globulin within 10 days, and maternal varicella is treated with acyclovir.

Intrapartum GBS prophylaxis uses IV penicillin G; cefazolin is used for low-risk penicillin allergy, and clindamycin (if the isolate is susceptible) or vancomycin for high-risk allergy, ideally started at least 4 hours before delivery.

Pregnant people with HIV take ART throughout pregnancy, and those with viral loads above 1,000 copies/mL near delivery receive IV zidovudine and a scheduled cesarean at 38 weeks.

Last updated: October 2026

Principles

Maternal infections threaten the pregnancy in three ways: direct fetal infection with anomalies or anemia, preterm birth or loss, and transmission at delivery. Gestational age at infection usually predicts severity: first-trimester infection causes structural damage, while later infection causes growth, neurologic, or hematologic effects.

TORCH and Viral Infections

Infection Transmission and Risk Fetal or Neonatal Effects Key Management

Cytomegalovirus (CMV) Saliva and urine of young children; transmission about 30%–40% after primary maternal infection, much lower after reactivation Most common congenital infection; sensorineural hearing loss, microcephaly, periventricular calcifications, chorioretinitis, FGR No routine screening (ACOG). Diagnose with IgM plus low IgG avidity . Amniotic fluid PCR at least 6 weeks after infection and after 21 weeks. High-dose valacyclovir for primary first-trimester infection reduced transmission in a trial; discuss with maternal-fetal medicine

Parvovirus B19 Respiratory droplets; teachers and parents of young children at risk; transmission about 30% Suppresses fetal red-cell production → anemia and nonimmune hydrops , highest risk before 20 weeks IgM/IgG serology after exposure. If acute infection: MCA peak systolic velocity Doppler every 1–2 weeks for 8–12 weeks ; intrauterine transfusion for severe anemia

Varicella Highly contagious; maternal pneumonia can be severe Congenital varicella syndrome (about 2% if infection before 20 weeks): limb hypoplasia, cicatricial skin scars, eye and CNS defects; neonatal varicella if the maternal rash appears from 5 days before to 2 days after delivery Exposed susceptible patient: VariZIG within 10 days . Maternal infection: oral acyclovir (IV for pneumonia). Newborn gets VariZIG when maternal rash timing is high risk

Rubella Respiratory; rare in the United States because of vaccination Congenital rubella syndrome : deafness, cataracts, heart defects (PDA, pulmonary stenosis); risk up to 90% with infection before 11 weeks Check immunity at the first visit; give MMR postpartum , never during pregnancy

Toxoplasmosis Undercooked meat, cat feces, unwashed produce Chorioretinitis, hydrocephalus, intracranial calcifications Spiramycin to reduce transmission; pyrimethamine, sulfadiazine, and folinic acid if fetal infection is confirmed

Measles Airborne; outbreaks resurged in 2025 Miscarriage, preterm birth, low birth weight; severe maternal pneumonia Susceptible pregnant contacts receive IV immune globulin within 6 days of exposure; MMR postpartum

Influenza and COVID-19 Respiratory Pregnancy raises risk of severe illness, preterm birth Vaccinate in any trimester (ACOG); treat influenza promptly with oseltamivir regardless of vaccination status or symptom duration

Zika virus Mosquito bite and sexual transmission Microcephaly and brain anomalies Avoid travel to areas with active outbreaks; condom use with exposed partners

Prevention counseling for every pregnant patient: wash hands after diaper changes and wiping a child's nose and mouth, don't share utensils or kiss young children on the mouth (CMV), avoid cleaning cat litter and wear gloves in soil (toxoplasmosis), cook meat thoroughly, and avoid unpasteurized dairy and cold deli meats (listeria).

Listeriosis

Listeria monocytogenes comes from unpasteurized dairy, soft cheeses, deli meats, and smoked seafood. Pregnant people are about 10 times more likely to be infected. Maternal illness is often a mild flu-like fever with myalgias, but infection can cause miscarriage, preterm labor, stillbirth, and neonatal sepsis or meningitis . Diagnose with blood cultures in a febrile pregnant patient with exposure, and treat with IV ampicillin (with or without gentamicin). Cephalosporins are not effective against Listeria .

Group B Streptococcus (GBS)

Screening: Rectovaginal culture at 36 0/7–37 6/7 weeks (ACOG 2020) for everyone except those already needing prophylaxis.

Intrapartum antibiotic prophylaxis (IAP) is indicated for: a positive culture this pregnancy; GBS bacteriuria at any count during this pregnancy; a prior infant with invasive GBS disease; or unknown status with labor before 37 weeks, rupture of membranes for 18 hours or more, intrapartum fever of 100.4 °F (38 °C) or higher, or a positive intrapartum NAAT.

Not needed: a planned cesarean before labor with intact membranes, even if GBS-positive.

Situation Regimen

No penicillin allergy Penicillin G 5 million units IV, then 2.5–3 million units every 4 hours until delivery (ampicillin 2 g IV, then 1 g every 4 hours, is an alternative)

Low-risk allergy (no anaphylaxis, angioedema, respiratory distress, or urticaria) Cefazolin 2 g IV, then 1 g every 8 hours

High-risk allergy Clindamycin 900 mg IV every 8 hours only if the isolate is susceptible; otherwise vancomycin

Prophylaxis is considered adequate when a beta-lactam is started at least 4 hours before delivery . Penicillin allergy testing during pregnancy helps many patients safely receive first-line therapy.

HIV in Pregnancy

Start or continue antiretroviral therapy (ART) for every pregnant person regardless of CD4 count, aiming for an undetectable viral load; check viral load around 34–36 weeks to plan delivery.

Viral load >1,000 copies/mL (or unknown) near delivery: IV zidovudine during labor and a scheduled cesarean at 38 weeks before labor or membrane rupture.

Suppressed viral load: Vaginal birth is appropriate, and IV zidovudine is not required.

The newborn receives antiretroviral prophylaxis. Since 2023, federal perinatal guidelines support shared decision-making about breastfeeding for people with sustained viral suppression on ART; replacement feeding eliminates postnatal transmission.

With treatment, perinatal transmission is below 1% , compared with about 25% without intervention.

Hepatitis B and C in Pregnancy

Screen for HBsAg and HCV antibody in every pregnancy. For HBsAg-positive patients, check HBV DNA; tenofovir starting at 28–32 weeks is recommended when HBV DNA exceeds 200,000 IU/mL, and every newborn of an HBsAg-positive mother receives HBIG plus hepatitis B vaccine within 12 hours . Hepatitis C is treated postpartum; avoid invasive fetal procedures when possible, and breastfeeding is encouraged unless nipples are cracked and bleeding.